The pathophysiology of polycystic ovary syndrome

Clinical Endocrinology

Volumn 60, Issue 1, 2004, Pages 1-17

  Tsilchorozidou, Tasoula ^a   Overton, Caroline ^a   Conway, Gerard S ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; GONADOTROPIN; GROWTH FACTOR; HYDROCORTISONE; LEPTIN; METFORMIN; STEROID 21 MONOOXYGENASE; VASOCONSTRICTOR AGENT;

ALOPECIA; ANOVULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CUSHING SYNDROME; ECHOGRAPHY; ENZYME DEFICIENCY; ENZYME RELEASE; FEEDBACK SYSTEM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; INFERTILITY; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SPONTANEOUS ABORTION; STROMA; TECHNOLOGY;

ADRENAL GLANDS; ADULT; ANDROGENS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYDROCORTISONE; INSULIN RESISTANCE; LEPTIN; LUTEINIZING HORMONE; OVARY; PITUITARY GLAND; POLYCYSTIC OVARY SYNDROME;

EID: 0842330821     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2003.01842.x     Document Type: Review

References (189)

1. Abbott, D.H., Dumesic, D.A., Eisner, J.R., Colman, R.J. & Kemnitz, J.W. (1998) Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends of Endocrinology and Metabolism, 9, 62-67.
2. Abbott, D.H., Dumesic, D.A. & Franks, S. (2002) Developmental origin of polycystic ovary syndrome: a hypothesis. Journal of Endocrinology, 174, 1-5.
3. Achard, C. & Thiers, J. (1921) Le virilisme pilaire et son association a l'insuffisance glucolytique (diabetes des femmes a barb). Bulletin of the Academy of National Medicine, 86, 51-64.
4. Adams, J., Franks, S., Polson, D.W., Mason, H.D., Abdulwahid, N., Tucker, M., Morris, D.V, Price, J. & Jacobs, H.S. (1985) Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet, 2, 1375-1379.
5. Adashi, E.Y., Hsueh, A.J., Bambino, T.H. & Yen, S.S. (1981) Disparate effect of clomiphene and tamoxifen on pituitary gonadotropin release in vitro. American Journal of Physiology, 240, E125-E130.
6. Agrawal, R., Sladkevicius, P., Engmann, L., Conway, O.S., Payne, N.N., Bekis, J., Tan, S.L., Campbell, S. & Jacobs, H.S. (1998) Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Human Reproduction, 13, 651-655.
7. Al-Hendy, A., Moshynska, O., Saxena, A. & Feyles, V (2000) Association between mutations of the follicle-stimulating hormone receptor and repeated twinning. Lancet, 356, 914.
8. Almahbobi, G., Anderiesz, C., Hutchinson, P., McFarlane, J.R., Wood, C. & Trounson, A.O. (1996) Functional integrity of granulosa cells from polycystic ovaries. Clinical Endocrinology, 44, 571-580.
9. Andersen, P., Seljeflot, I., Abdelnoor, M., Arnesen, H., Dale, P.O., Lovik, A. & Birkeland, K. (1995) Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 44, 611-616.
10. Andrew, R., Phillips, D.I. & Walker, B.R. (1998) Obesity and gender influence cortisol secretion and metabolism in man. Journal of Clinical Endocrinology and Metabolism, 83, 1806-1809.
11. Apter, D., Butzow, T., Laughlin, G.A. & Yen, S.S. (1994) Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 79, 119-125.
12. Atiomo, W.U., Pearson, S., Shaw, S., Prentice, A. & Dubbins, P. (2000) Ultrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS). Ultrasound in Medicine and Biology, 26, 977-980.
13. Bach, L.A. (1999) The insulin-like growth factor system: basic and clinical aspects. Australian and New Zealand Journal of Medicine, 29, 355-361.
14. Balen, A.H., Conway, G.S., Kaltsas, G., Techatrasak, K., Manning, P.J., West, C. & Jacobs, H.S. (1995) Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human Reproduction, 10, 2107-2111.
15. Barbieri, R.L., Makris, A. & Ryan, K.J. (1984) Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstetrics and Gynecology, 64, 73S-80S.
16. Barnes, R.B., Rosenfield, R.L., Burstein, S. & Ehrmann, D.A. (1989) Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. New England Journal of Medicine, 320, 559-565.
17. Barnes, R.B., Rosenfield, R.L., Ehrmann, D.A., Cara, J.F., Cuttler, L., Levitsky, L.L. & Rosenthal, I.M. (1994) Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. Journal of Clinical Endocrinology and Metabolism, 79, 1328-1333.
18. Berga, S.L. & Yen, S.S. (1989) Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clinical Endocrinology, 30, 177-184.
19. Bergh, C., Carlsson, B., Olsson, J.H., Selleskog, U & Hillensjo, T. (1993) Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertility and Sterility, 59, 323-331.
20. Birdsall, M.A., Farquhar, C.M. & White, H.D. (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Annals of International Medicine, 126, 32-35.
21. Bonora, E., Zavaroni, I., Alpi, O., Pezzarossa, A., Bruschi, F., Dall'Aglio, E., Guerra, L., Coscelli, C. & Butturini, U. (1987) Relationship between blood pressure and plasma insulin in non-obese and obese non-diabetic subjects. Diabetologia, 30, 719-723.
22. Book, C.B. & Dunaif, A. (1999) Selective insulin resistance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 84, 3110-3116.
23. Burghen, G.A., Givens, J.R. & Kitabchi, A.E. (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism, 50, 113-116.
24. Cara, J.F., Fan, J., Azzarello, J. & Rosenfield, R.L. (1990) Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. Journal of Clinical Investigation, 86, 560-565.
25. Carey, A.H., Waterworth, D., Patel, K., White, D., Little, J., Novelli, P., Franks, S. & Williamson, R. (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Human Molecular Genetics, 3, 1873-1876.
26. Cataldo, N.A. & Giudice, L.C. (1992) Follicular fluid insulin-like growth factor binding protein profiles in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 74, 695-697.
27. Chang, R.J., Nakamura, R.M., Judd, H.L. & Kaplan, S.A. (1983) Insulin resistance in nonobese patients with polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism, 57, 356-359.
28. Cheung, A.P., Lu, J.K. & Chang, R.J. (1997) Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment. Human Reproduction, 12, 1156-1164.
29. Chin, D., Shackleton, C., Prasad, VK., Kohn, B., David, R., Imperato-McGinley, J., Cohen, H., McMahon, D.J. & Oberfield, S.E. (2000) Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism, 13, 253-259.
30. Christman, G.M., Randolph, J.F., Kelch, R.P. & Marshall, J.C. (1991) Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism, 72, 1278-1285.
31. Clayton, R.N., Ogden, V., Hodgkinson, J., Worswick, L., Rodin, D.A., Dyer, S. & Meade, T.W. (1992) How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clinical Endocrinology, 37, 127-134.
32. Conn, J.J., Jacobs, H.S. & Conway, G.S. (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clinical Endocrinology, 52, 81-86.
33. Conway, G.S., Jacobs, H.S., Holly, J.M. & Wass, J.A. (1990) Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome. Clinical Endocrinology, 33, 593-603.
34. Conway, G.S., Avey, C. & Rumsby, G. (1994) The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome. Human Reproduction, 9, 1681-1683.
35. Conway, G.S., Conway, E., Walker, C., Hoppner, W., Gromoll, J. & Simoni, M. (1999) Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clinical Endocrinology, 51, 97-99.
36. Cresswell, J.L., Barker, D.J., Osmond, C., Egger, P., Phillips, D.I. & Fraser, R.B. (1997) Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet, 350, 1131-1135.
37. Dahlgren, E., Johansson, S., Lindstedt, G., Knutsson, F., Oden, A., Janson, P.O., Mattson, L.A., Crona, N. & Lundberg, P.A. (1992) Women with polycystic ovary syndrome wedge resected in 1956-65: a long-term follow-up focusing on natural history and circulating hormones. Fertility and Sterility, 57, 505-513.
38. Dale, P.O., Tanbo, T., Vaaler, S. & Abyholm, T. (1992) Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertility and Sterility, 58, 487-491.
39. Dawson, S. & Henney, A. (1992) The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis, 95, 105-117.
40. Dejager, S., Pichard, C., Giral, P., Bruckert, E., Federspield, M.C., Beucler, I. & Turpin, G. (2001) Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clinical Endocrinology, 54, 455-462.
41. Diamanti-Kandarakis, E., Mitrakou, A., Hennes, M.M., Platanissiotis, D., Kaklas, N., Spina, J., Georgiadou, E., Hoffmann, R.G., Kissebah, A.H. & Raptis, S. (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 44, 525-531.
42. Diamanti-Kandarakis, E., Mitrakou, A., Raptis, S., Tolis, G. & Duleba, A.J. (1998) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 83, 2699-2705.
43. Diamanti-Kandarakis, E., Spina, G., Kouli, C. & Migdalis, I. (2001) Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. Journal of Clinical Endocrinology and Metabolism, 86, 4666-4673.
44. Dumesic, D.A., Abbott, D.H., Eisner, J.R. & Goy, R.W. (1997) Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertility and Sterility, 67, 155-163.
45. Dunaif, A. (1986) Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome? Journal of Clinical Endocrinology and Metabolism, 63, 215-221.
46. Dunaif, A. (1995) Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. American Journal of Medicine, 98, 33S-39S.
47. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews, 18, 774-800.
48. Dunaif, A. & Finegood, D.T. (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81, 942-947.
49. Dunaif, A., Graf, M., Mandeli, J., Laumas, V. & Dobrjansky, A. (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism, 65, 499-507.
50. Dunaif, A., Segal, K.R., Futterweit, W. & Dobrjansky, A. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165-1174.
51. Dunaif, A., Green, G., Futterweit, W. & Dobrjansky, A. (1990) Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 70, 699-704.
52. Dunaif, A., Segal, K.R., Shelley, D.R., Green, G., Dobrjansky, A. & Licholai, T. (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes, 41, 1257-1266.
53. Dunaif, A., Xia, J., Book, C.B., Schenker, E. & Tang, Z. (1995) Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. Journal of Clinical Investigation, 96, 801-810.
54. Dunaif, A., Scott, D., Finegood, D., Quintana, B. & Whitcomb, R. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81, 3299-3306.
55. Ehrmann, D.A., Rosenfield, R.L., Barnes, R.B., Brigell, D.F. & Sheikh, Z. (1992) Detection of functional ovarian hyperandrogenism in women with androgen excess. New England Journal of Medicine, 327, 157-162.
56. Ehrmann, D.A., Stuns, J., Byrne, M.M., Karrison, T., Rosenfield, R.L. & Polonsky, K.S. (1995a) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation, 96, 520-527.
57. Ehrmann, D.A., Barnes, R.B. & Rosenfield, R.L. (1995b) Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Reviews, 16, 322-353.
58. Ehrmann, D.A., Cavaghan, M.K., Imperial, J., Sturis, J., Rosenfield, R.L. & Polonsky, K.S. (1997a) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 524-530.
59. Ehrmann, D.A., Schneider, D.J., Sobel, B.E., Cavaghan, M.K., Imperial, J., Rosenfield, R.L. & Polonsky, K.S. (1997b) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 2108-2116.
60. Eisner, J.R., Dumesic, D.A., Kemnitz, J.W. & Abbott, D.H. (2000) Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. Journal of Clinical Endocrinology and Metabolism, 85, 1206-1210.
61. Eisner, J.R., Barnett, M.A., Dumesic, D.A. & Abbott, D.H. (2002) Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertility and Sterility, 77, 167-172.
62. Elkind-Hirsch, K.E., Valdes, C.T. & Malinak, L.R. (1993) Insulin resistance improves in hyperandrogenic women treated with Lupron. Fertility and Sterility, 60, 634-641.
63. Fauser, B.C., Pache, T.D., Hop, W.C., de Jong, F.H. & Dahl, K.D. (1992) The significance of a single serum LH measurement in women with cycle disturbances: discrepancies between immunoreactive and bioactive hormone estimates. Clinical Endocrinology, 37, 445-452.
64. Ferrannini, E., Buzzigoli, G., Bonadonna, R., Giorico, M.A., Oleggini, M., Graziadei, L., Pedrinelli, R., Brandi, L. & Bevilacqua, S. (1987) Insulin resistance in essential hypertension. New England Journal of Medicine, 317, 350-357.
65. Finken, M.J., Andrews, R.C., Andrew, R. & Walker, B.R. (1999) Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases. Journal of Clinical Endocrinology and Metabolism, 84, 3316-3321.
66. Fox, R. (1999) Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea. Australian and New Zealand Journal of Obstetrics and Gynaecology, 39, 63-68.
67. Franks, S., Gharani, N., Waterworth, D, Batty, S., White, D., Williamson, R. & McCarthy, M. (1997) The genetic basis of polycystic ovary syndrome. Human Reproduction, 12, 2641-2648.
68. Franks, S., Gharani, N. & McCarthy, M. (2001) Candidate genes in polycystic ovary syndrome. Human Reproduction Update, 7, 405-410.
69. Geffner, M.E., Kaplan, S.A., Bersch, N., Golde, D.W., Landaw, E.M. & Chang, R.J. (1986) Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertility and Sterility, 45, 327-333.
70. Gharani, N., Waterworth, D.M., Williamson, R. & Franks, S. (1996) 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. Journal of Clinical Endocrinology and Metabolism, 81, 4174.
71. Gharib, S.D., Wierman, M.E., Shupnik, M.A. & Chin, W.W. (1990) Molecular biology of the pituitary gonadotropins. Endocrine Reviews, 11, 177-199.
72. Gilling-Smith, C., Willis, D.S., Beard, R.W. & Franks, S. (1994) Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. Journal of Clinical Endocrinology and Metabolism, 79, 1158-1165.
73. Glueck, C.J., Wang, P., Kobayashi, S., Phillips, H. & Sieve-Smith, L. (2002) Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and Sterility, 77, 520-525.
74. Glueck, C.J., Phillips, H., Cameron, D., Sieve-Smith, L. & Wang, P. (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertility and Sterility, 75, 46-52.
75. Guzick, D.S., Wing, R., Smith, D., Berga, S.L. & Winters, S.J. (1994) Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility and Sterility, 61, 598-604.
76. Guzick, D.S., Talbott, E.O., Sutton-Tyrrell, K., Herzog, H.C., Kuller, L.H. & Wolfson, S.K. Jr (1996) Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. American Journal of Obstetrics and Gynecology, 174, 1224-1229; discussion 1229-32.
77. Hacihanefioglu, B., Seyisoglu, H., Karsidag, K., Elter, K., Aksu, F., Yilmaz, T. & Gurol, A.O. (2000) Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome. Fertility and Sterility, 73, 261-265.
78. Hamsten, A., de Faire, U., Walldius, G., Dahlen, G., Szamosi, A., Landou, C., Blomback, M. & Wiman, B. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet, 2, 3-9.
79. Hann, L.E., Hall, D.A., McArdle, C.R. & Seibel, M. (1984) Polycystic ovarian disease: sonographic spectrum. Radiology, 150, 531-534.
80. Hardie, L., Trayhurn, P., Abramovich, D. & Fowler, P (1997) Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy. Clinical Endocrinology, 47, 101-106.
81. Harris, M.I., Hadden, W.C., Knowler, W.C. & Bennett, P.H. (1987) Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 years. Diabetes, 36, 523-534.
82. Hayes, F.J., Taylor, A.E., Martin, K.A. & Hall, J.E. (1998) Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. Journal of Clinical Endocrinology and Metabolism, 83, 2343-2349.
83. Herbert, C.M., 3rd, Hill, G.A. & Diamond, M.P. (1990) The use of the intravenous glucose tolerance test to evaluate nonobese hyperandrogenemic women. Fertility and Sterility, 53, 647-653.
84. Hillier, S.G., Yong, E.L., Illingworth, P.J., Baird, D.T., Schwall, R.H. & Mason, A.J. (1991) Effect of recombinant inhibin on androgen synthesis in cultured human thecal cells. Molecular and Cellular Endocrinology, 75, R1-R6.
85. Holte, J., Bergh, T., Berne, C., Wide, L. & Lithell, H. (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 80, 2586-2593.
86. Horton, R., Pasupuletti, V & Antonipillai, I. (1993) Androgen induction of steroid 5 alpha-reductase may be mediated via insulin-like growth factor-I. Endocrinology, 133, 447-451.
87. Hsueh, A.J., Dahl, K.D., Vaughan, J., Tucker, E., Rivier, J., Bardin, C.W. & Vale, W. (1987) Heterodimers and homodimers of inhibin subunits have different paracrine action in the modulation of luteinizing hormone-stimulated androgen biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 84, 5082-5086.
88. Ibanez, L., Potau, N., Francois, I. & de Zegher, F. (1998) Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. Journal of Clinical Endocrinology and Metabolism, 83, 3558-3562.
89. Ibanez, L., Potau, N., Marcos, M.V. & de Zegher, F. (1999) Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. Journal of Clinical Endocrinology and Metabolism, 84, 4739-4741.
90. Imse, V., Holzapfel, G., Hinney, B., Kuhn, W. & Wuttke, W. (1992) Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. Journal of Clinical Endocrinology and Metabolism, 74, 1053-1061.
91. Jacobs, H.S. (1990) Insulin-like growth factor receptor. In: Insulin. (eds P. Cuatrecasas & S. Jacobs), pp. 269. Spriger-Verlag, New York.
92. Jacobs, H.S. & Conway, G.S. (1999) Leptin, polycystic ovaries and polycystic ovary syndrome. Human Reproduction Update, 5, 166-171.
93. Jahanfar, S., Eden, J.A., Nguyen, T., Wang, X.L. & Wilcken, D.E. (1997) A twin study of polycystic ovary syndrome and lipids. Gynecological Endocrinology, 11, 111-117.
94. Jakubowicz, D.J., Iuorno, M.J., Jakubowicz, S., Roberts, K.A. & Nestler, J.E. (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 87, 524-529.
95. Kahsar-Miller, M.D., Nixon, C., Boots, L.R., Go, R.C. & Azziz, R. (2001) Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertility and Sterility, 75, 53-58.
96. Keye, W.R. Jr & Jaffe, R.B. (1975) Strength-duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. I. Effects of varying duration of estradiol administration. Journal of Clinical Endocrinology and Metabolism, 41, 1003-1008.
97. Kiddy, D.S., Hamilton-Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M.J. & Franks, S. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology, 36, 105-111.
98. Lakhani, K., Constantinovici, N., Purcell, W.M., Fernando, R. & Hardiman, P. (2000) Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet, 356, 1166-1167.
99. Lanzone, A., Caruso, A., Di Simone, N., De Carolis, S., Fulghesu, A.M. & Mancuso, S. (1995) Polycystic ovary disease. A risk factor for gestational diabetes? Journal of Reproductive Medicine, 40, 312-316.
100. Lees, C., Jurkovic, D., Zaidi, J. & Campbell, S. (1998) Unexpected effect of a nitric oxide donor on uterine artery Doppler velocimetry in oligomenorrheic women with polycystic ovaries. Ultrasound in Obstetrics and Gynecology, 11, 129-132.
101. Legro, R.S., Driscoll, D., Strauss, J.F., 3rd, Fox, J. & Dunaif, A. (1998) Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proceedings of the National Academy of Sciences of the United States of America, 95, 14956-14960.
102. Legro, R.S., Kunselman, A.R., Dodson, W.C. & Dunaif, A. (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology and Metabolism, 84, 165-169.
103. Legro, R.S., Bentley-Lewis, R., Driscoll, D., Wang, S.C. & Dunaif, A. (2002) Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. Journal of Clinical Endocrinology and Metabolism, 87, 2128-2133.
104. Le Roith, D., McGuinness, M., Shemer, J., Stannard, B., Lanau, F., Faria, T.N., Kato, H., Werner, H., Adamo, M. & Roberts Jr, C.T. (1992) Insulin-like growth factors. Biology Signals, 1, 173-181.
105. Lindstedt, G., Lundberg, P.A., Lapidus, L., Lundgren, H., Bengtsson, C. & Bjorntorp, P. (1991) Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-year follow-up of population study of women in Gothenburg, Sweden. Diabetes, 40, 123-128.
106. Lobo, R.A., Granger, L.R., Paul, W.L., Goebelsmann, U. & Mishell, D.R. Jr (1983) Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 145, 496-503.
107. Lockwood, G.M., Muttukrishna, S., Groome, N.P., Matthews, D.R. & Ledger, W.L. (1998) Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. Journal of Clinical Endocrinology and Metabolism, 83, 1730-1735.
108. Luppa, P., Muller, B., Jacob, K., Kimmig, R., Strowitzki, T., Hoss, C., Weber, M.M., Engelhardt, D. & Lobo, R.A. (1995) Variations of steroid hormone metabolites in serum and urine in polycystic ovary syndrome after nafarelin stimulation: evidence for an altered corticoid excretion. Journal of Clinical Endocrinology and Metabolism, 80, 280-288.
109. Mahabeer, S., Jialal, I., Norman, R.J., Naidoo, C., Reddi, K. & Joubert, S.M. (1989) Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease. Hormone and Metabolic Research, 21, 502-506.
110. Mais, V, Kazer, R.R., Cetel, N.S., Rivier, J., Vale, W & Yen, S.S. (1986) The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin- releasing hormone antagonist as a probe. Journal of Clinical Endocrinology and Metabolism, 62, 1250-1255.
111. Marshall, J.C. & Eagleson, C.A. (1999) Neuroendocrine aspects of polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America, 28, 295-324.
112. Marshall, J.C., Dalkin, A.C., Haisenleder, D.J., Paul, S.J., Ortolano, G.A. & Kelch, R.P. (1991) Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. Recent Progress in Hormone Research, 47, 155-187; discussion 188-189.
113. Mason, H.D., Willis, D.S., Holly, J.M. & Franks, S. (1994) Insulin preincubation enhances insulin-like growth factor-II (IGF-II) action on steroidogenesis in human granulosa cells. Journal of Clinical Endocrinology and Metabolism, 78, 1265-1267.
114. Michelmore, K., Ong, K., Mason, S., Bennett, S., Perry, L., Vessey, M., Balen, A. & Dunger, D. (2001) Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clinical Endocrinology, 55, 439-446.
115. Mitwally, M.F., Kuscu, N.K. & Yalcinkaya, T.M. (1999) High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Human Reproduction, 14, 2700-2703.
116. Moghetti, P., Tosi, F., Castello, R., Magnani, C.M., Negri, C., Brun, E., Furlani, L., Caputo, M. & Muggeo, M. (1996a) The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. Journal of Clinical Endocrinology and Metabolism, 81, 952-960.
117. Moghetti, P., Castello, R., Negri, C., Tosi, F., Spiazzi, G.G., Brun, E., Balducci, R., Toscano, V. & Muggeo, M. (1996b) Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. Journal of Clinical Endocrinology and Metabolism, 81, 881-886.
118. Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E. & Muggeo, M. (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism, 85, 139-146.
119. Morales, A.J., Laughlin, G.A., Butzow, T., Maheshwari, H., Baumann, G. & Yen, S.S. (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. Journal of Clinical Endocrinology and Metabolism, 81, 2854-2864.
120. Moran, C. & Azziz, R. (2001) The role of the adrenal cortex in polycystic ovary syndrome. Obstetrics and Gynecology Clinics of North America, 28, 63-75.
121. Mowszowicz, I., Melanitou, E., Kirchhoffer, M.O. & Mauvais-Jarvis, P. (1983) Dihydrotestosterone stimulates 5α-reductase activity in pubic skin fibroblasts. Journal of Clinical Endocrinology and Metabolism, 56, 320-325.
122. Nagamani, M., Van Dinh, T. & Kelver, M.E. (1986) Hyperinsulinemia in hyperthecosis of the ovaries. American Journal of Obstetrics and Gynecology, 154, 384-389.
123. Nelson, VL., Legro, R.S., Strauss, J.F. & 3rd & McAllister, J.M. (1999) Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Molecular Endocrinology, 13, 946-957.
124. Nelson, V.L., Qin Kn, K.N., Rosenfield, R.L., Wood, J.R., Penning, T.M., Legro, R.S., Strauss IIIrd, J.F. & McAllister, J.M. (2001) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 86, 5925-5933.
125. Nestler, J.E. (1993) Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? Journal of Clinical Endocrinology and Metabolism, 76, 273-274.
126. Nestler, J.E. (1997) Insulin regulation of human ovarian androgens. Human Reproduction, 12 (Suppl. 1), 53-62.
127. Nestler, J.E. & Jakubowicz, D.J. (1996) Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine, 335, 617-623.
128. Nestler, J.E. Barlascini, C.O. Matt, D.W. Steingold, K.A. Plymate, S.R. Clore, J.N. & Blackard, WG. (1989) Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 68, 1027-1032.
129. Nestler, J.E. Jakubowicz, D.J. de Vargas, A.F. Brik, C. Quintero, N. & Medina, F. (1998a) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. Journal of Clinical Endocrinology and Metabolism, 83, 2001-2005.
130. Nestler, J.E. Jakubowicz, D.J. Evans, W.S. & Pasquali, R. (1998b) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine, 338, 1876-1880.
131. O'Meara, N.M. Blackman, J.D. Ehrmann, D.A. Barnes, R.B. Jaspan, J.B. Rosenfield, R.L. & Polonsky, K.S. (1993) Defects in β-cell function in functional ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 76, 1241-1247.
132. Oksanen, L. Tiitinen, A. Kaprio, J. Koistinen, H.A. Karonen, S. & Kontula, K. (2000) No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Molecular Human Reproduction, 6, 873-876.
133. Orchard, T.J. Becker, D.J. Bates, M. Kuller, L.H. & Drash, A.L. (1983) Plasma insulin and lipoprotein concentrations: an atherogenic association? American Journal of Epidemiology, 118, 326-337.
134. Ovesen, P. Moller, J. Ingerslev, H.J. Jorgensen, J.O. Mengel, A. Schmitz, O. Alberti, K.G. & Moller, N. (1993) Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 11, 1636-1640.
135. Paradisi, G. Steinberg, H.O. Hempfling, A. Cronin, J. Hook, G. Shepard, M.K. & Baron, A.D. (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 103, 1410-1415.
136. Pastor, C.L. Griffin-Korf, M.L. Aloi, J.A. Evans, W.S. & Marshall, J.C. (1998) Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. Journal of Clinical Endocrinology and Metabolism, 83, 582-590.
137. Pierpoint, T. McKeigue, P.M. Isaacs, A.J. Wild, S.H. & Jacobs, H.S. (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology, 51, 581-586.
138. Pirwany, I.R. Yates, R.W. Cameron, I.T. & Fleming, R. (1999) Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Human Reproduction, 14, 2963-2968.
139. Pirwany, I.R. Fleming, R. Greer, I.A. Packard, C.J. & Sattar, N. (2001) Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clinical Endocrinology, 54, 447-453.
140. Pollare, T. Lithell, H. & Berne, C. (1990) Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism: Clinical and Experimental, 39, 167-174.
141. Poretsky, L. Grigorescu, F. Seibel, M. Moses, A.C. & Flier, J.S. (1985) Distribution and characterization of insulin and insulin-like growth factor I receptors in normal human ovary. Journal of Clinical Endocrinology and Metabolism, 61, 728-734.
142. Prelevic, G.M. Wurzburger, M.I. Balint-Peric, L. & Nesic, J.S. (1990) Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet, 336, 900-903.
143. Prelevic, G.M. Beljic, T. Balint-Peric, L. & Ginsburg, J. (1995) Cardiac flow velocity in women with the polycystic ovary syndrome. Clinical Endocrinology, 43, 677-681.
144. Prelevic, G.M. Wood, J. & Okolo, S. (1996) Peripheral blood flow in young women with polycystic ovary syndrome. Journal of Endocrinology, 151 (Suppl.), 13.
145. Reaven, G.M. (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
146. Robinson, S. Kiddy, D. Gelding, S.V. Willis, D. Niththyananthan, R. Bush, A. Johnston, D.G. & Franks, S. (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology, 39, 351-355.
147. Rodin, A. Thakkar, H. Taylor, N. & Clayton, R. (1994) Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. New England Journal of Medicine, 330, 460-465.
148. Rodin, D.A. Bano, G. Bland, J.M. Taylor, K. & Nussey, S.S. (1998) Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clinical Endocrinology, 49, 91-99.
149. Rosen, E.D. & Spiegelman, B.M. (1999) Tumor necrosis factor-a as a mediator of insulin resistance of obesity. Current Opinion in Endocrinology and Diabetes, 6, 170-176.
150. Rosenfield, R.L. Barnes, R.B. Cara, J.F. & Lucky, A.W. (1990) Dysregulation of cytochrome P450c 17α as the cause of polycystic ovarian syndrome. Fertility and Sterility, 53, 785-791.
151. Rosenfield, R.L. Barnes, R.B. & Ehrmann, D.A. (1994) Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 79, 1686-1692.
152. Rouru, J. Anttila, L. Koskinen, P. Penttila, T.A. Irjala, K. Huupponen, R. & Koulu, M. (1997) Serum leptin concentrations in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 82, 1697-1700.
153. Rubin, R.R. Fujimoto, W.Y. Marrero, D.G. Brenneman, T. Charleston, J.B. Edelstein, S.L. Fisher, E.B. Jordan, R. Knowler, W.C. Lichterman, L.C. Prince, M. & Rowe, P.M. (2002) The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials, 23, 157-171.
154. Sampson, M. Kong, C. Patel, A. Unwin, R. & Jacobs, H.S. (1996) Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAl-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology, 45, 623-629.
155. San Roman, G.A. & Magoffin, D.A. (1992) Insulin-like growth factor binding proteins in ovarian follicles from women with polycystic ovarian disease: cellular source and levels in follicular fluid. Journal of Clinical Endocrinology and Metabolism, 75, 1010-1016.
156. Schachter, M. Balen, A.M. Patel, A. & Jacobs, H.S. (1996) Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone. Gynecological Endocrinology, 10, 327-335.
157. Seppala, M. & Hirvonen, E. (1975) Raised serum prolactin levels associated with hirsutism and amenorrhoea. British Medical Journal, 4, 144-145.
158. Shoham, Z. Conway, G.S. Patel, A. & Jacobs, H.S. (1992) Polycystic ovaries in patients with hypogonadotropic hypogonadism: similarity of ovarian response to gonadotropin stimulation in patients with polycystic ovarian syndrome. Fertility and Sterility, 58, 37-45.
159. Siddle, K. Soos, M.A. Field, C.E. & Nave, B.T. (1994) Hybrid and atypical insulin/insulin-like growth factor I receptors. Hormone Research, 41 (Suppl. 2), 56-64; discussion 65.
160. Sorbara, L.R. Tang, Z. Cama, A. Xia, J. Schenker, E. Kohanski, R.A. Poretsky, L. Koller, E. Taylor, S.I. & Dunaif, A. (1994) Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome. Metabolism: Clinical and Experimental, 43, 1568-1574.
161. Spinder, T. Spijkstra, J.J. Gooren, L.J. & Burger, C.W. (1989) Pulsatile luteinizing hormone release and ovarian steroid levels in female-to-male transsexuals compared to heterosexual women. Psychoneuroendocrinology, 14, 97-102.
162. Stein, I.F. & Leventhal, M. (1935) Amenorrhoea associated with bilateral polycystic ovaries. Aerican Journal of Obstetrics and Gynecology, 29, 181-191.
163. Stewart, P.M. Shackleton, C.H. Beastall, G.H. & Edwards, C.R. (1990) 5α-Reductase activity in polycystic ovary syndrome. Lancet, 335, 431-433.
164. Talbot, J.A. Bicknell, E.J. Rajkhowa, M. Krook, A. O'Rahilly, S. & Clayton, R.N. (1996) Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism, 81, 1979-1983.
165. Techatraisak, K. Conway, G.S. & Rumsby, G. (1997) Frequency of a polymorphism in the regulatory region of the 17α-hydroxylase-17,20-lyase (CYP 17) gene in hyperandrogenic states. Clinical Endocrinology, 46, 131-134.
166. Timor-Tritsch, I.E. & Rotten, S. (1998) Transvaginal Sonography. Elsevier. Science Publishing Co, Inc., New York.
167. Tulandi, T. Saleh, A. Morris, D. Jacobs, H.S. Payne, N.N. & Tan, S.L. (2000) Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome. Fertility and Sterility, 74, 585-588.
168. Turner, E.I. Watson, M.J. Perry, L.A. & White, M.C. (1992) Investigation of adrenal function in women with oligomenorrhoea and hirsutism (clinical PCOS) from the north-east of England using an adrenal stimulation test. Clinical Endocrinology, 36, 389-397.
169. Unger, J.W. Livingston, J.N. & Moss, A.M. (1991) Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Progress in Neurobiology, 36, 343-362.
170. Urbanek, M. Legro, R.S. Driscoll, D.A. Azziz, R. Ehrmann, D.A. Norman, R.J. Strauss, J.F. 3rd, Spielman, R.S. & Dunaif, A. (1999) Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proceedings of the National Academy of Sciences of the United States of America, 96, 8573-8578.
171. Urbanek, M., Legro, R.S., Driscoll, D., Strauss IIIrd, J.F., Dunaif, A., & Spielman, R.S., (2000a) Searching for the polycystic ovary syndrome genes. Journal of Pediatric Endocrinology and Metabolism, 13 (Suppl. 5), 1311-1313.
172. Urbanek, M., Wu, X., Vickery, K.R., Kao, L.C., Christenson, L.K., Schneyer, A., Legro, R.S., Driscoll, D.A., Strauss IIIrd, J.F., Dunaif, A., & Spielman, R.S., (2000b) Allelic variants of the follistatin gene in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 85, 4455-4461.
173. Vandermolen, D.T. Ratts, V.S. Evans, W.S. Stovall, D.W. Kauma, S.W. & Nestler, J.E. (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility, 75, 310-315.
174. Velazquez, E.M. Mendoza, S. Hamer, T. Sosa, F. & Glueck, C.J. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperin-sulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism: Clinical and Experimental, 43, 647-654.
175. Velazquez, E.M. Mendoza, S.G. Wang, P & Glueck, C.J. (1997) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism: Clinical and Experimental, 46, 454-457.
176. Venturoli, S. Porcu, E. Fabbri, R. Magrini, O. Gammi, L. Paradisi, R. Forcacci, M. Bolzani, R. & Flamigni, C. (1988) Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clinical Endocrinology, 28, 93-107.
177. Waldstreicher, J. Santoro, N.F. Hall, J.E. Filicori, M. & Crowley Jr, W.F. (1988) Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. Journal of Clinical Endocrinology and Metabolism, 66, 165-172.
178. Walker, B.R., Rodin, A., Taylor, N.F. & Clayton, R.N. (2000) Endogenous inhibitors of IIβ-hydroxysteroid dehydrogenase type I do not explain abnormal cortisol metabolism in polycystic ovary syndrome. Clinical Endocrinology, 52, 77-80.
179. Waterworth, D.M. Bennett, S.T. Gharani, N. McCarthy, M.I. Hague, S. Batty, S. Conway, G.S. White, D. Todd, J.A. Franks, S. & Williamson, R. (1997) Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet, 349, 986-990.
180. Wild, R.A. Grubb, B. Hartz, A. Van Nort, J.J. Bachman, W. & Bartholomew, M. (1990) Clinical signs of androgen excess as risk factors for coronary artery disease. Fertility and Sterility, 54, 255-259.
181. Wild, S. Pierpoint, T. McKeigue, P. & Jacobs, H. (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology, 52, 595-600.
182. Willis, D. & Franks, S. (1995) Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-1 insulin-like growth factor receptor. Journal of Clinical Endocrinology and Metabolism, 80, 3788-3790.
183. Willis, D. Mason, H. Gilling-Smith, C. & Franks, S. (1996) Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. Journal of Clinical Endocrinology and Metabolism, 81, 302-309.
184. Yen, S.S. Vela, P. & Rankin, J. (1970) Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism, 30, 435-442.
185. Yen, S.S. Laughlin, G.A. & Morales, A.J. (1993) Interface between extra-and intraovarian factors in polycystic ovarian syndrome. Annals of the New York Academy of Sciences, 687, 98-111.
186. Zavaroni, I. Bonora, E. Pagliara, M. Dall'Aglio, E. Luchetti, L. Buonanno, G. Bonati, P.A. Bergonzani, M. Gnudi, L. Passeri, M. & et al. (1989) Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. New England Journal of Medicine, 320, 702-706.
187. Zawadeski, J.K. & Dunaif, A. (1992) Diagnostic criteria for PCOS: towards a more rational approach. In: PCOS. Boston, (eds A. Dunaif, J.R. Givens, P.P. Haseltine & G.R. Merriam), pp. 377-84. PCOS. Boston: Blackwell Scientific.
188. Zhang, L.H., Rodriguez, H., Ohno, S. & Miller, W.L. (1995) Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proceedings of the National Academy of Sciences of the United States of America, 92, 10619-10623.
189. Zimmermann, S., Phillips, R.A., Dunaif, A., Finegood, D.T., Wilkenfeld, C., Ardeljan, M., Gorlin, R. & Krakoff, L.R. (1992) Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. Journal of Clinical Endocrinology and Metabolism, 75, 508-513.